Pharmas are from Mars, Payers are from Venus
Pharma needs to step up its sales pitch, looking beyond a drug's top attributes, to convince payers that their drugs are worth the cost.
View ArticleAmid misspent billions, the promise of personalized medicine
The Institute of Medicine has released a report putting the cost of unnecessary medical care at $750 billion a year and counting. What does it mean for pharmas? Depends on how you read it.
View ArticleHHS expands 9/11 health program to cover cancers
The Department of Health and Human Services observed the anniversary of the September 11, 2001 attacks by extending coverage of a program for first responders sickened by their work at Ground Zero, the...
View ArticleCompany news: AstraZeneca, Novartis, Teva
AstaZeneca avoids a Lipitor moment, FDA approves Novartis med for Cushing's, and Teva ventures into South Korea. Plus: a closer look at health exchanges
View ArticleStudies show cheaper drugs don't add up to greater use
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
View ArticleHigh deductibles linked to lower Rx fills and cancer screenings
A study highlights medical service trends among patients with high-deductible plans but lacks insight on health impact and long-term costs.
View ArticleDoctors could use more info on health exchanges: study
A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.
View ArticleBusiness briefs: Allergan, Incyte, Medtronic, Aetna
Allergan asks FDA to reconsider Restatis generics requirements, Incyte's Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna's...
View ArticleBusiness briefs: AbbVie, FDA, and health spending projections
AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than...
View ArticleACA enrollment misses target
Official numbers are pending, but Reuters notes enrollment appears to be just 3% of the government's goal.
View ArticleWhat payer concerns? Sovaldi ahead of curve
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
View ArticleMM&M's top reads of 2014
A look at the content that grabbed most reader interest over the past year.
View ArticleBetter Rx coverage associated with outcomes lift: study
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
View ArticleOncologist's petition is latest salvo, as drug-pricing issue rises to new...
Drugmakers face increasing pressure on pricing from insurers and PBMs.
View ArticlePartners+Simons CEO takes helm at parent company Myelin Health
With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.
View ArticleInhaled insulin stymied by drive for value
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
View ArticleFive things for pharma marketers to know: Thursday, July 2
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
View ArticleFive things for pharma marketers to know: Tuesday, July 14
The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure...
View ArticleFive things for pharma marketers to know: Friday, July 24
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug,...
View ArticleFive things for pharma marketers to know: Thursday, December 7, 2017
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
View Article
